论文部分内容阅读
目的探讨异丙托溴铵联合舒利迭治疗重度哮喘的临床效果。方法 78例重度哮喘的患者,随机分为对照组和治疗组,每组39例,比较两组患者的临床效果。结果治疗组的总有效率为94.87%,明显高于对照组的87.18%,两组相比差异有统计学意义(P<0.05);治疗组患者的一秒用力呼气容积(FEV1)、用力肺力活量(FVC)以及FEV1/FVC的值都明显的升高,明显优于对照组,两组相比差异有统计学意义(P<0.05)。结论异丙托溴铵联合舒利迭治疗重度哮喘的患者,疗效确切,值得在临床上推广使用。
Objective To investigate the clinical efficacy of ipratropium bromide combined with seretide in the treatment of severe asthma. Methods A total of 78 patients with severe asthma were randomly divided into control group and treatment group, 39 cases in each group. The clinical effects of two groups were compared. Results The total effective rate of the treatment group was 94.87%, which was significantly higher than 87.18% of the control group, the difference was statistically significant (P <0.05); the forced expiratory volume one second (FEV1) The values of FVC and FEV1 / FVC were significantly higher than those of the control group, the difference was statistically significant (P <0.05). Conclusion Ipratropium bromide combined with seretide in patients with severe asthma, curative effect is exact, it is worth in the clinical promotion.